Richelle C Charles Selected Research

Antibodies

11/2023	T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19.
5/2023	Shigella O-specific polysaccharide functional IgA responses mediate protection against shigella infection in an endemic high-burden setting.
1/2023	Predicting Vibrio cholerae infection and symptomatic disease: a systems serology study.
12/2022	Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.
3/2022	Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection.
1/2022	Longevity of memory B cells and antibodies, as well as the polarization of effector memory helper T cells, are associated with disease severity in patients with COVID-19 in Bangladesh.
1/2022	The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
1/2021	Humoral signatures of protective and pathological SARS-CoV-2 infection in children.
1/2021	Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
1/2021	Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richelle C Charles Research Topics

Disease

38	Cholera 02/2024 - 01/2011
31	Infections 10/2023 - 08/2010
15	COVID-19 11/2023 - 05/2020
15	Typhoid Fever (Typhoid) 07/2023 - 08/2010
3	Bacterial Infections (Bacterial Infection) 10/2020 - 10/2011
3	Convalescence 01/2016 - 04/2015
2	Bacillary Dysentery (Shigellosis) 05/2023 - 01/2023
2	Reinfection 01/2023 - 01/2019
2	Bacteremia 01/2016 - 08/2010
1	Common Variable Immunodeficiency 11/2023
1	Severe Acute Respiratory Syndrome 06/2022
1	Coronavirus Infections 03/2022
1	Coinfection 01/2022
1	Parasitic Diseases (Parasitic Disease) 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Acute Disease 01/2021
1	Dehydration (Water Stress) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 12/2020
1	Respiratory Insufficiency (Respiratory Failure) 12/2020
1	Disease Progression 12/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020
1	Diarrhea 01/2018
1	Communicable Diseases (Infectious Diseases) 11/2015
1	HIV Infections (HIV Infection) 09/2015
1	Headache (Headaches) 04/2015
1	Fever (Fevers) 03/2014
1	Paratyphoid Fever 03/2014

Drug/Important Bio-Agent (IBA)

27	AntigensIBA 07/2023 - 08/2010
21	AntibodiesIBA 11/2023 - 03/2014
20	O Antigens (O Antigen)IBA 02/2024 - 11/2012
19	Cholera Vaccines FDA Link 02/2024 - 08/2012
18	VaccinesIBA 02/2024 - 08/2010
16	Immunoglobulin A (IgA)IBA 05/2023 - 01/2013
16	Immunoglobulin G (IgG)IBA 01/2023 - 01/2013
12	Immunoglobulin M (IgM)IBA 12/2022 - 05/2014
10	Conjugate VaccinesIBA 11/2023 - 10/2011
10	LipopolysaccharidesIBA 10/2023 - 11/2012
7	Polysaccharides (Glycans)IBA 01/2021 - 06/2013
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2010
5	Cholera ToxinIBA 02/2024 - 01/2016
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2017
4	Monoclonal AntibodiesIBA 01/2023 - 12/2016
4	ImmunosorbentsIBA 12/2022 - 03/2014
4	EnzymesIBA 12/2022 - 03/2014
3	cholera vaccine CVD 103-HgRIBA 01/2023 - 01/2018
3	Neuraminidase (Sialidase)IBA 01/2022 - 12/2016
3	CytokinesIBA 01/2021 - 08/2012
3	Hemolysin Proteins (Hemolysins)IBA 10/2020 - 03/2014
3	shancholIBA 01/2016 - 05/2014
2	Tetanus ToxinIBA 11/2023 - 01/2015
2	Capsules (Microcapsules)IBA 10/2023 - 01/2021
2	Complement System Proteins (Complement)IBA 01/2023 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 01/2019
2	Nucleic AcidsIBA 01/2023 - 11/2015
2	Phosphates (Orthophosphate)IBA 01/2021 - 01/2021
2	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2021 - 02/2014
2	Neutralizing AntibodiesIBA 10/2020 - 10/2020
2	Blood Group Antigens (Blood Groups)IBA 11/2019 - 05/2014
2	InterferonsIBA 01/2018 - 06/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2011
1	DukoralIBA 02/2024
1	Rituximab (Mabthera)FDA Link 11/2023
1	TCVSIBA 05/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	EpitopesIBA 12/2022
1	Peptides (Polypeptides)IBA 12/2022
1	ChAdOx1 nCoV-19IBA 06/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Bacterial PolysaccharidesIBA 11/2021
1	CarbohydratesIBA 01/2021
1	BuffersIBA 01/2021
1	colitoseIBA 01/2021
1	Viral ProteinsIBA 12/2020
1	Viral AntigensIBA 12/2020
1	SARS-CoV-2 spike proteinIBA 10/2020
1	Coronavirus ReceptorsIBA 01/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2019
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2018
1	Dual OxidasesIBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 01/2018
1	Interferon Regulatory Factor-7 (Interferon Regulatory Factor 7)IBA 01/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018
1	Complementary DNA (cDNA)IBA 01/2016
1	LeptinIBA 08/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2015
1	squaric acidIBA 01/2015
1	Interleukin-17 (Interleukin 17)IBA 06/2014
1	Interleukin-13IBA 06/2014
1	Interleukin-9 (Interleukin 9)IBA 06/2014
1	Bacterial Proteins (Bacterial Protein)IBA 05/2013
1	4-O-carboxymethylascochlorinIBA 11/2012
1	Bovine Serum AlbuminIBA 11/2012
1	1-oleoyl-2-stearoylphosphatidylcholineIBA 11/2012
1	Typhoid-Paratyphoid Vaccines (Typhoid Vaccines)FDA Link 08/2010

Therapy/Procedure

2	Therapeutics 11/2023 - 12/2020
1	Fluid Therapy (Oral Rehydration Therapy) 01/2018